• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

仿生抗原纳米颗粒引发针对流感的可控保护性免疫应答。

Biomimetic antigenic nanoparticles elicit controlled protective immune response to influenza.

机构信息

Department of Chemistry and Biochemistry, Center for Bio-Inspired Nanomaterials, Montana State University, Bozeman, Montana 59717, United States.

出版信息

ACS Nano. 2013 Apr 23;7(4):3036-44. doi: 10.1021/nn4006544. Epub 2013 Apr 10.

DOI:10.1021/nn4006544
PMID:23540530
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3773536/
Abstract

Here we present a biomimetic strategy toward nanoparticle design for controlled immune response through encapsulation of conserved internal influenza proteins on the interior of virus-like particles (VLPs) to direct CD8+ cytotoxic T cell protection. Programmed encapsulation and sequestration of the conserved nucleoprotein (NP) from influenza on the interior of a VLP, derived from the bacteriophage P22, results in a vaccine that provides multistrain protection against 100 times lethal doses of influenza in an NP specific CD8+ T cell-dependent manner. VLP assembly and encapsulation of the immunogenic NP cargo protein is the result of a genetically programmed self-assembly making this strategy amendable to the quick production of vaccines to rapidly emerging pathogens. Addition of adjuvants or targeting molecules were not required for eliciting the protective response.

摘要

在这里,我们提出了一种仿生策略,通过将保守的内部流感蛋白包封在病毒样颗粒 (VLPs) 的内部,来设计纳米颗粒以控制免疫反应,从而指导 CD8+细胞毒性 T 细胞的保护。从噬菌体 P22 衍生而来的 VLPs 中,对流感的保守核蛋白 (NP) 进行编程包封和隔离,可产生一种疫苗,以 NP 特异性 CD8+T 细胞依赖的方式提供针对 100 倍致死剂量流感的多株保护。VLPs 的组装和免疫原性 NP 货物蛋白的包封是遗传编程自组装的结果,这一策略使得快速生产疫苗以应对快速出现的病原体成为可能。不需要添加佐剂或靶向分子来引发保护反应。

相似文献

1
Biomimetic antigenic nanoparticles elicit controlled protective immune response to influenza.仿生抗原纳米颗粒引发针对流感的可控保护性免疫应答。
ACS Nano. 2013 Apr 23;7(4):3036-44. doi: 10.1021/nn4006544. Epub 2013 Apr 10.
2
A biomimetic VLP influenza vaccine with interior NP/exterior M2e antigens constructed through a temperature shift-based encapsulation strategy.一种通过基于温度变化的包封策略构建的、具有内部核蛋白(NP)/外部基质蛋白2(M2e)抗原的仿生病毒样颗粒(VLP)流感疫苗。
Vaccine. 2020 Aug 27;38(38):5987-5996. doi: 10.1016/j.vaccine.2020.07.015. Epub 2020 Jul 24.
3
A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.一种 VLP 疫苗可诱导针对 H5N1 和 H1N1 亚型流感病毒的广谱交叉保护抗体免疫。
PLoS One. 2012;7(8):e42363. doi: 10.1371/journal.pone.0042363. Epub 2012 Aug 7.
4
Vaccine Efficacy Induced by 2009 Pandemic H1N1 Virus-Like Particles Differs from that Induced by Split Influenza Virus.2009 年大流行的 H1N1 病毒样颗粒诱导的疫苗效力与裂解流感病毒诱导的不同。
Immunol Invest. 2020 Oct;49(7):781-793. doi: 10.1080/08820139.2019.1694539. Epub 2019 Nov 27.
5
Incorporation of conserved nucleoprotein into influenza virus-like particles could provoke a broad protective immune response in BALB/c mice and chickens.将保守核蛋白整合到流感病毒样颗粒中可在BALB/c小鼠和鸡中引发广泛的保护性免疫反应。
Virus Res. 2015 Jan 2;195:35-42. doi: 10.1016/j.virusres.2014.09.018.
6
Structural basis for the development of avian virus capsids that display influenza virus proteins and induce protective immunity.展示流感病毒蛋白并诱导保护性免疫的禽病毒衣壳发育的结构基础。
J Virol. 2015 Mar;89(5):2563-74. doi: 10.1128/JVI.03025-14. Epub 2014 Dec 17.
7
Adjuvants that stimulate TLR3 or NLPR3 pathways enhance the efficiency of influenza virus-like particle vaccines in aged mice.佐剂刺激 TLR3 或 NLPR3 通路可提高流感样病毒颗粒疫苗在老年小鼠中的效率。
Vaccine. 2011 Nov 8;29(48):9081-92. doi: 10.1016/j.vaccine.2011.09.051. Epub 2011 Sep 28.
8
Mono- and quadri-subtype virus-like particles (VLPs) containing H10 subtype elicit protective immunity to H10 influenza in a ferret challenge model.含有H10亚型的单亚型和四亚型病毒样颗粒(VLP)在雪貂攻毒模型中对H10流感病毒引发保护性免疫。
Vaccine. 2016 Oct 17;34(44):5235-5242. doi: 10.1016/j.vaccine.2016.09.012. Epub 2016 Sep 20.
9
Highly immunogenic influenza virus-like particles containing B-cell-activating factor (BAFF) for multi-subtype vaccine development.含有 B 细胞激活因子(BAFF)的高免疫原性流感病毒样颗粒,用于多亚型疫苗开发。
Antiviral Res. 2019 Apr;164:12-22. doi: 10.1016/j.antiviral.2019.02.004. Epub 2019 Feb 6.
10
Development of a Pan-H1 Influenza Vaccine.开发一种泛 H1 流感疫苗。
J Virol. 2018 Oct 29;92(22). doi: 10.1128/JVI.01349-18. Print 2018 Nov 15.

引用本文的文献

1
Virus-like particle encapsulation of functional proteins: advances and applications.功能性蛋白质的病毒样颗粒封装:进展与应用
Theranostics. 2024 Nov 4;14(19):7604-7622. doi: 10.7150/thno.103127. eCollection 2024.
2
Advanced technologies for the development of infectious disease vaccines.传染病疫苗开发的先进技术。
Nat Rev Drug Discov. 2024 Dec;23(12):914-938. doi: 10.1038/s41573-024-01041-z. Epub 2024 Oct 21.
3
Cell-penetrating peptides TAT and 8R functionalize P22 virus-like particles to enhance tissue distribution and retention .

本文引用的文献

1
Use of the interior cavity of the P22 capsid for site-specific initiation of atom-transfer radical polymerization with high-density cargo loading.利用 P22 衣壳的内部腔室进行高载量货物的原子转移自由基聚合的位点特异性引发。
Nat Chem. 2012 Oct;4(10):781-8. doi: 10.1038/nchem.1442. Epub 2012 Aug 26.
2
Airborne transmission of influenza A/H5N1 virus between ferrets.雪貂之间甲型流感病毒 H5N1 的空气传播。
Science. 2012 Jun 22;336(6088):1534-41. doi: 10.1126/science.1213362.
3
Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets.
细胞穿透肽TAT和8R使P22病毒样颗粒功能化,以增强组织分布和滞留。
Front Vet Sci. 2024 Sep 3;11:1460973. doi: 10.3389/fvets.2024.1460973. eCollection 2024.
4
Decoration of Hcp1 protein to virus-like particles as a vaccine delivery platform.将Hcp1蛋白修饰到病毒样颗粒上作为一种疫苗递送平台。
Infect Immun. 2024 Mar 12;92(3):e0001924. doi: 10.1128/iai.00019-24. Epub 2024 Feb 14.
5
Exploration of nanozymes in viral diagnosis and therapy.纳米酶在病毒诊断与治疗中的探索。
Exploration (Beijing). 2022 Jan 25;2(1):20210086. doi: 10.1002/EXP.20210086. eCollection 2022 Feb.
6
P22-Based Nanovaccines against Enterohemorrhagic Escherichia coli.基于P22的抗肠出血性大肠杆菌纳米疫苗
Microbiol Spectr. 2023 Mar 21;11(2):e0473422. doi: 10.1128/spectrum.04734-22.
7
Bacteriophage P22 Capsid as a Pluripotent Nanotechnology Tool.噬菌体 P22 衣壳作为一种多用途纳米技术工具。
Viruses. 2023 Feb 13;15(2):516. doi: 10.3390/v15020516.
8
Biomimicry in nanotechnology: a comprehensive review.纳米技术中的仿生学:全面综述
Nanoscale Adv. 2022 Dec 22;5(3):596-614. doi: 10.1039/d2na00571a. eCollection 2023 Jan 31.
9
Biomaterial-Based In Situ Cancer Vaccines.基于生物材料的原位癌症疫苗。
Adv Mater. 2024 Oct;36(43):e2210452. doi: 10.1002/adma.202210452. Epub 2023 Apr 25.
10
Assembly of Protein Cages for Drug Delivery.用于药物递送的蛋白质笼组装。
Pharmaceutics. 2022 Nov 26;14(12):2609. doi: 10.3390/pharmaceutics14122609.
实验性改造的流感 H5 HA 可使重组 H5 HA/H1N1 病毒在雪貂中通过呼吸道飞沫传播。
Nature. 2012 May 2;486(7403):420-8. doi: 10.1038/nature10831.
4
Virus-like particle-induced protection against MRSA pneumonia is dependent on IL-13 and enhancement of phagocyte function.病毒样颗粒诱导的抗耐甲氧西林金黄色葡萄球菌肺炎的保护作用依赖于 IL-13 和增强吞噬细胞功能。
Am J Pathol. 2012 Jul;181(1):196-210. doi: 10.1016/j.ajpath.2012.03.018. Epub 2012 May 26.
5
Engineering nano- and microparticles to tune immunity.工程化纳米和微米颗粒以调节免疫。
Adv Mater. 2012 Jul 24;24(28):3724-46. doi: 10.1002/adma.201200446. Epub 2012 May 29.
6
Nanoreactors by programmed enzyme encapsulation inside the capsid of the bacteriophage P22.通过噬菌体 P22 衣壳内的编程酶包封制备纳米反应器。
ACS Nano. 2012 Jun 26;6(6):5000-9. doi: 10.1021/nn300545z. Epub 2012 May 31.
7
New technologies for influenza vaccines.流感疫苗新技术。
Hum Vaccin Immunother. 2012 Jan;8(1):45-58. doi: 10.4161/hv.8.1.18859. Epub 2012 Jan 1.
8
Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines.诱导病毒特异性细胞毒性T淋巴细胞作为开发广泛保护性流感疫苗的基础。
J Biomed Biotechnol. 2011;2011:939860. doi: 10.1155/2011/939860. Epub 2011 Oct 5.
9
Targeting B cell responses in universal influenza vaccine design.靶向设计通用流感疫苗中的 B 细胞反应。
Trends Immunol. 2011 Nov;32(11):524-31. doi: 10.1016/j.it.2011.08.007. Epub 2011 Sep 21.
10
Recent advances in microparticle and nanoparticle delivery vehicles for mucosal vaccination.微粒和纳料给药载体在黏膜免疫接种中的最新进展。
Curr Top Microbiol Immunol. 2012;354:75-99. doi: 10.1007/82_2011_140.